{"organizations": [], "uuid": "bf1b39dd6f720091fcc2c2c94405af581ffdd794", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180111.html", "section_title": "Archive News &amp; Video for Thursday, 11 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-eurocine-vaccines-gets-authorized/brief-eurocine-vaccines-gets-authorized-to-conduct-phase-i-ii-clinical-study-idUSFWN1P60XE", "country": "US", "domain_rank": 408, "title": "BRIEF-Eurocine Vaccines Gets Authorized To Conduct Phase I/II Clinical Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-11T23:00:00.000+02:00", "replies_count": 0, "uuid": "bf1b39dd6f720091fcc2c2c94405af581ffdd794"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-eurocine-vaccines-gets-authorized/brief-eurocine-vaccines-gets-authorized-to-conduct-phase-i-ii-clinical-study-idUSFWN1P60XE", "ord_in_thread": 0, "title": "BRIEF-Eurocine Vaccines Gets Authorized To Conduct Phase I/II Clinical Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 11 (Reuters) - EUROCINE VACCINES AB:\n* EUROCINE VACCINES OBTAINS AUTHORIZATION TO CONDUCT THE NEXT STUDY WITH IMMUNOSE™ FLU\n* GOT AUTHORIZATION TO CONDUCT A PHASE I/II CLINICAL STUDY ON QUADRIVALENT INFLUENZA VACCINE CANDIDATE IMMUNOSE™ FLU\n* RESULTS CAN BE EXPECTED SECOND HALF OF 2018. * AUTHORIZATIONS TO CONDUCT STUDY RECEIVED FROM ‍SWEDISH MEDICAL PRODUCTS AGENCY AND ETHICS COMMITTEE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-11T23:00:00.000+02:00", "crawled": "2018-01-12T18:47:07.013+02:00", "highlightTitle": ""}